ArticleOncoTargets and therapy2025
Integrative Multi-Omics and Functional Characterization Reveal MCM4 as a Key Oncogenic Regulator in Hepatocellular Carcinoma.
Article in OncoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a highly lethal malignancy with limited therapeutic options and poor prognosis. Identifying robust prognostic biomarkers and therapeutic targets is essential for improving patient outcomes. Minichromosome maintenance complex component 4 (MCM4), a DNA replication licensing factor, has been associated various malignancies, yet its involvement in HCC remains underexplored. Methods: We performed integrative bioinformatics analyses on three public HCC datasets (GSE14520, GSE56545, and GSE84402) to identify consistently dysregulated genes. Functional enrichment analyses were conducted using GO, KEGG, and Reactome databases. PPI networks were constructed via STRING. The expression and prognostic value of MCM4 were evaluated using GEPIA, Human Protein Atlas, and KM-Plotter. Single-cell and spatial transcriptomics from the HCCDB were analyzed to explore MCM4 localization. Functional roles of MCM4 were validated in vitro using siRNA-mediated knockdown and plasmid-based overexpression in HepG2 and Huh7 cells. Results: MCM4 was identified as a consistently upregulated gene in HCC and was associated with poor overall, disease-free, recurrence-free, and disease-specific survival. Single-cell and spatial transcriptomic analyses revealed MCM4 enrichment in proliferative tumor regions. Functional assays demonstrated that MCM4 promotes HCC cell growth, motility, invasiveness, and enhances EMT and stemness. Conversely, MCM4 knockdown attenuated these malignant phenotypes. Conclusion: Our study establishes MCM4 as a key regulator of HCC progression and a potential prognostic biomarker. These findings suggest that MCM4 may serve as a potential target and underscore integrative and spatial transcriptomic approaches in cancer biomarker discovery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.